Zebrafish Data Presented at International Conferences

 

 

Oxford, UK, 9 April 2008 - Summit Corporation plc (AIM: SUMM), a leading UK biotechnology company, announces that its scientists have presented data that highlight the utility and power of zebrafish in the discovery and development of new drugs at two leading, international drug safety and toxicology conferences. The presentations to an audience of key opinion leaders from industry and academia were given at the Society of Toxicology Annual Meeting (Seattle, WA, USA - March 16-20) and the British Toxicology Society Annual Congress (Guildford, UK - April 7-9).

   

Copies of the presentations are available on request from Summit at investors@summitplc.com.

 

Zebrafish are well-characterised model organisms and are used in the screening of potential drug candidates to provide invaluable in vivo data from the earliest stages of drug discovery and throughout the development process. Summit has developed a range of high-throughput safety pharmacology and toxicity screens and also several important zebrafish disease models that can be used to identify and evaluate potential new drug candidates.

 

Summit has developed a profitable service business offering its zebrafish technology to pharmaceutical and biotechnology companies to evaluate their own drug programmes. These technologies also have the potential to reduce costs and accelerate the drug discovery process. As such, Summit is establishing itself as a highly valued industrial partner for the life sciences industry and can count seven of the top ten largest pharmaceutical companies as its customers in this area.